This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Apricus Biosciences Launches Educational Video Series Focused On Its Newly Approved Erectile Dysfunction Drug, Vitaros®

Apricus Biosciences, Inc. (Nasdaq:APRI), based in San Diego, announced today that Dr. Bassam Damaj, Ph.D., Chairman, President and Chief Executive Officer, is now appearing in a series of online educational videos focused on its newly approved erectile dysfunction drug, Vitaros ®, which was approved by Health Canada in November 2010. The video series can be seen on the company’s website. The company stated that the video series was created to provide answers to commonly asked questions about the newly approved drug, which is the first approved erectile dysfunction treatment in the western hemisphere that is applied topically.

According to Dr. Damaj, “The educational video series provides clear, concise answers to the general public about Apricus Bio’s recently approved erectile dysfunction drug, Vitaros, a proprietary, topically-applied , first-line therapy for erectile dysfunction. The videos consist of a series of one-on-one news interviews with me, regarding the company’s plans, timetables, and marketing prospects for Vitaros.”

In one of the interviews, Dr. Damaj states that Apricus Bio is currently seeking to establish partnerships on both country-specific and regional terms, with the goal of entering into a number of licensing and partnership deals in 2011. Dr. Damaj also indicated that the company hopes to sell Vitaros in Canada through a partnership that is targeted for the second or third quarter of 2011. He stated that the company intends to file for marketing authorization in Europe in April of 2011. Dr. Damaj also stated that Warner Chilcott, which owns rights to Vitaros in the U.S., continues to pursue approval of the drug through the U.S. Food and Drug Administration.

Dr. Damaj stated that, according to 2009 IMS data, the ex-U.S. market size for sales of approved erectile dysfunction drugs is approximately $2 billion annually. He also noted that, in a survey conducted on behalf of the company by D2 Market Research, 65 urologists surveyed stated that they would likely prescribe Vitaros to approximately 27 percent of their current patients who suffer from erectile dysfunction. Dr. Damaj further stated that projections for the size of the ex-U.S. market for approved drugs to treat erectile dysfunction do not take into account patients who cannot take current erectile dysfunction drugs due to cardiac conditions, hypertension, diabetes, obesity, and prostatectomy or do not respond to existing oral medications.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.30 -0.92%
FB $118.08 0.55%
GOOG $695.81 0.50%
TSLA $234.18 0.80%
YHOO $35.97 -0.11%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs